Psychedelic drug development and business strategy converge in Bulletin 228, from Eli Lilly's atai deal to FDA guidance, patent disputes, and Resilient's resubmission plans

Psychedelic drug development, corporate dealmaking, patent conflict, and regulatory strategy intersect in a roundup centered on Eli Lilly's relationship with atai, ongoing tensions around the GH Research and Beckley intellectual property dispute, reactions to new FDA guidance, and Resilient's next regulatory move. The focus spans how large pharmaceutical interest can reshape the sector, how patent standoffs may influence competition and ownership around novel treatments, and how FDA guidance is being interpreted by companies and observers navigating trial design and approval pathways. Resilient's planned resubmission adds a concrete near-term milestone, tying business execution to regulatory risk and showing how capital, IP, and agency expectations are collectively shaping the current psychedelic medicines landscape.